Multiple types of relapses in MOG antibody disease.

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Multiple Sclerosis and Related Disorders

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.msard.2023.104613PMID 36931080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.

  2023cited by this paper
• Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management

  2022cited by this paper
• Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders

  2021cited by this paper
• Predictors of relapse in MOG antibody associated disease: a cohort study

  2021cited by this paper
• Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes

  2021cited by this paper
• Myelin-oligodendrocyte glycoprotein antibody-associated disease.

  2021cited by this paper
• Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.

  2020cited by this paper
• Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies

  2020cited by this paper
• Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes

  2019cited by this paper
• Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

  2019cited by this paper
• Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

  2018cited by this paper
• Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

  2017cited by this paper
• Clinical presentation and prognosis in MOG-antibody disease: a UK study

  2017cited by this paper
• Assessing changes in relapse rates in multiple sclerosis

  2010cited by this paper

• Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

  2026cites this paper
• Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

  2024cites this paper
• Delimiting MOGAD as a disease entity using translational imaging

  2023cites this paper
• [Typical and atypical optic neuritis].

  2023cites this paper